



News Release

September 13, 2018
Maruho Co., Ltd.

Maruho Launches Blood-flow Accelerative/Skin-moisturizing Agent “Hirudoid® Foam 0.3%”

Osaka (Japan), September 13, 2018 – Maruho Co., Ltd (“Maruho”, Head Office: Osaka, Japan, President and CEO: Koichi Takagi) announces it launched blood-flow accelerative/skin-moisturizing agent “Hirudoid® Foam 0.3%” (INN: heparinoid, hereinafter referred to as “the product”), in Japan today.

The product is a foam agent (topical aerosol agent) that ejects fine-grained foam from the container and contains the same active ingredients in the same concentration as "Hirudoid®" products currently available. The product is easily spread and can be quickly applied to a wide range of affected areas. Maruho hopes the product will expand treatment options and improve adherence for patients suffering from asteatosis and other skin diseases.

Maruho will continue to contribute to patients suffering from skin diseases by providing a stable supply and promoting the proper use of the product and other approved prescription drug "Hirudoid®" products.



Product profile: Hirudoid® Foam 0.3%

INN	Heparinoid
Formulation/Dose	Topical aerosol containing 3.0mg of heparinoid per 1 gram
Indication	Thrombophlebitis (including hemorrhoids), Pain and inflammatory diseases owing to circulatory disturbance (induration and pain after injection), Chilblain, Treatment and prevention of hypertrophic scar or keloid, Keratoderma tylodes palmaris progressiva, Asteatosis, Swelling, hematoma, tendosynovitis, myalgia, arthritis after trauma (bruise, sprain, and/or contusion), Torticollis muscularis (infant)
Dosage and Administration	Usually, apply an appropriate amount of the product to the affected area once to several times a day.
NHI Drug Price Standard	1g 22.20yen
Packaging	Can: Liquid concentrate 92g x 10
Date of Approval	February 15, 2018
Date of NHI Price Listing	June 15, 2018
Date of Launch	September 13, 2018
Manufacturer	Maruho Co., Ltd

About Adherence

The degree to which a patient actively participates in treatment. For a medicine prescribed by a doctor, it refers to the degree that a patient understands the disease, the significance of the medication, and voluntarily maintains the dosage and administration.

About Maruho

Maruho Co., Ltd. has its headquarters in Osaka and leads Japan in research and development, manufacturing and commercialization of dermatological products. Founded in 1915, Maruho has 1,459 employees, and net sales were approximately 79.95 billion yen in its fiscal year ending September 30, 2017. Pursuing its long-term corporate vision of "Excellence in Dermatology," Maruho is striving to improve the health and quality of life of people all over the world.

For more information, please visit www.maruho.co.jp/english

Contact Information:

Maruho Co., Ltd.

Corporate Communications Dept.

Roger Matthews

Tel: +81-(0)6-6371-8831 Fax: +81-(0)6-6376-8679

Email: kouhou@mii.maruho.co.jp